Adding Eprenetapopt to Maintenance Azacitidine Promising After HCT in MDS/AML
Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.
All articles by John Eckman
Responses to COVID-19 Vaccines Persist at 6 Months in Patients With Cancer
Researchers observed persistent anti-RBD antibodies at 6 months after the second dose of an mRNA COVID-19 vaccine and a 20-fold increase in anti-RBD antibodies after the third dose.
Orteronel Does Not Improve Overall Survival in Prostate Cancer
Orteronel is likely not effective when compared with recently approved agents, according to researchers.
Lenalidomide Maintenance Superior to Bortezomib for Myeloma Patients With Abn1q
Among patients with Abn1q, those who received bortezomib-based maintenance had significantly worse progression-free survival and overall survival.
COVID-19 Vaccine Appears Effective in Cancer Patients on Active Treatment
At 1 year after vaccination, no cases of COVID-19 had been reported.
Triplet Bests Doublet in Stage IVA-IVB Nasopharyngeal Carcinoma
Induction with paclitaxel, cisplatin, and capecitabine proved more effective than cisplatin plus fluorouracil.
AI System Deemed ‘Promising’ for Breast Cancer Detection
The proportion of screen-detected cancers not identified by the AI system was less than 20%.
Tool Helps Lymphoma Survivors Understand Implications of Lung Cancer Screening
Researchers sought to determine whether a decision aid tool could help survivors of Hodgkin lymphoma understand lung cancer screening.
US Melanoma Incidence May Be Stabilizing for First Time in a Century
Data suggest the overall incidence of melanoma in the United States is stabilizing after nearly a century of continuous increase.
Lymphopenia Tied to Risk of Infection After Radiotherapy
Measuring lymphocytes during or after radiotherapy could provide useful information about infection risk, according to researchers.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...